The Level of Neuregulin-1 after Traumatic Brain Injury and Formation of Post-Traumatic Epilepsy

Gazaryan, L.M.; Selyanina, N. V.; Karakulova, Yu. V.; Sosnin, D. Yu.

doi:10.1007/s10517-019-04492-2

Cited by 3 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We could not find any studies on post-brain insult epilepsy assessing biomarkers in the saliva or urine of patients who developed epilepsy post-brain injuries. The studies represent populations from 11 distinct countries: 8 from China, [14][15][16][17][18][19][20][21] 3 from the United States, [22][23][24] 2 each from India, 25,26 Italy, 27,28 and Spain, 29,30 1 each from Japan, 31 Nigeria, 32 and Russia, 33 and 2 multicentric studies each from Ghana and Nigeria, 34 and Uganda and South Africa. 35 The publication years ranged from 2010 to 2022.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Common Pathways of Epileptogenesis in Patients With Epilepsy Post–Brain Injury

Misra,

Khan,

Lam

et al. 2023

Neurology

View full text Add to dashboard Cite

Background and Objective:Epilepsy may result from various brain injuries, including stroke (ischemic and hemorrhagic), traumatic brain injury, and infections. Identifying shared common biological pathways and biomarkers of the epileptogenic process initiated by the different injuries may lead to novel targets for preventing the development of epilepsy. We systematically reviewed biofluid biomarkers to test their association with the risk of post-brain injury epilepsy.Methods:We searched articles until January 25, 2022, in MEDLINE, Embase, PsycINFO, Web of Science, and Cochrane. The primary outcome was the difference in mean biomarker levels in patients with and without post-brain injury epilepsy. We used the modified quality score on prognostic studies for risk of bias assessment. We calculated each biomarker’s pooled standardized mean difference (SMD) and 95% confidence intervals (CI). Molecular interaction network and enrichment analyses were conducted in Cytoscape. (PROSPERO CRD42021297110)Results:We included 22 studies with 1499 cases with post-brain injury epilepsy and 7929 controls without post-brain injury epilepsy. Forty-five biomarkers in blood or cerebrospinal fluid (CSF) were investigated with samples collected at disparate time points. Of 22 studies, 21 had a moderate-to-high risk of bias. Most biomarkers (28/45) were investigated in single studies; only nine provided validation data, and studies used variable definitions for early and late-onset seizures. A meta-analysis was possible for 19 biomarkers. Blood glucose levels in four studies were significantly higher in patients with post-stroke epilepsy (PSE) than without PSE (SMD 0.44; CI 0.19 to 0.69). From individual studies, 15 biomarkers in blood and seven in CSF were significantly associated with post-brain injury epilepsy. Enrichment analysis identified that the significant biomarkers (IL6, IL1β) were predominantly inflammation related.Discussion:We cannot yet recommend using the reported biomarkers for designing anti-epileptogenesis trials or use in the clinical setting because of methodological heterogeneity, bias in the included studies, and insufficient validation studies. Even though our analyses indicate the plausible role of inflammation in epileptogenesis, this is likely not the only mechanism. For example, an individual’s genetic susceptibilities might contribute to his risk of epileptogenesis after brain injury. Rigorously designed biomarker studies with methods acceptable to the regulatory bodies should be conducted.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Eight studies (36.4%) had a high risk of bias, [20][21][22]24,[31][32][33][34] 13 studies (59.1%) had a moderate risk of bias, [14][15][16][17][18][19]23,[25][26][27][28][29]35 and only 1 study (4.5%) had a low risk of bias 30 (eFigure 1, links.lww.com/WNL/D32). Only 8 of 22 studies prospectively collected data.…”

Section: Risk Of Bias (Quality) Assessmentmentioning

confidence: 99%

Common Pathways of Epileptogenesis in Patients With Epilepsy Post–Brain Injury

Misra,

Khan,

Lam

et al. 2023

Neurology

View full text Add to dashboard Cite

show abstract

“…A study comparing mean serum level of NRG-1 measured using ELISA in patients with traumatic brain injury (35.96 ± 7.40 ng/mL) (mean ± SD) and traumatic brain injury with post-traumatic epilepsy (49.55 ± 14.02 ng/mL) were much higher than control (29.25 ± 5.51 ng/mL). Study control consisted of 10 (aged 31 ± 6 years) healthy individuals (Gazaryan et al, 2019). NRG-1 in human serum was measured using ELISA in a study by Zhao et al (2022) to be 3.97 ± 2.37 pg/mL (mean ± SD) in 80 healthy control subjects.…”

Section: Endogenous Level Of Nrg-1 In Humanmentioning

confidence: 99%

A review on the safety of growth factors commonly used in cultivated meat production

Huang,

Ko,

Paes

et al. 2024

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

Growth factors are commonly added to cell culture media in cellular agriculture to mimic the endogenous process of proliferation and differentiation of cells. Many of these growth factors are endogenous to humans and known to be present in the edible tissues and milk of food animals. However, there is little or no information on the use of growth factors intentionally added in food production before the advent of cultivated meat. Ten commonly used growth factors have been reviewed to include information on their mode of action, bioavailability, occurrence in food and food animals, endogenous levels in humans, as well as exposure and toxicological information drawn from relevant animal studies and human clinical trials with a focus on oral exposure. In addition, a comparison of homology of growth factors was done to compare the sequence homology of growth factors from humans and domestic animal species commonly consumed as food, such as bovine, porcine, and poultry. This information has been gathered as the starting point to determine the safety of use of growth factors in cultivated meat meant for human consumption. The change in levels of growth factors measured in human milk and bovine milk after pasteurization and high‐temperature treatment is discussed to give an indication of how commercial food processing can affect the levels of growth factors in food. The concept of substantial equivalence is also discussed together with a conservative exposure estimation. More work on how to integrate in silico assessments into the routine safety assessment of growth factors is needed.

show abstract

Genetic and molecular basis of epilepsy-related cognitive dysfunction

Zhu

Chen

et al. 2020

Epilepsy & Behavior

View full text Add to dashboard Cite

The Level of Neuregulin-1 after Traumatic Brain Injury and Formation of Post-Traumatic Epilepsy

Cited by 3 publications

References 11 publications

Common Pathways of Epileptogenesis in Patients With Epilepsy Post–Brain Injury

Common Pathways of Epileptogenesis in Patients With Epilepsy Post–Brain Injury

A review on the safety of growth factors commonly used in cultivated meat production

Genetic and molecular basis of epilepsy-related cognitive dysfunction

Contact Info

Product

Resources

About